Gemfibrozil

This product is a lipid-regulating drug of the clofibric acid derivative class. Its mechanism of action in lowering blood lipids is not yet fully understood. It may involve peripheral fat decomposition, reduce the liver's uptake of free fatty acids and reduce the formation of triglycerides in the liver, inhibit the synthesis of very low-density lipoprotein apolipoproteins and reduce the production of very low-density lipoproteins. This product reduces blood triglycerides and increases blood high-density lipoprotein concentrations. Although it can slightly reduce blood low-density lipoprotein cholesterol blood concentrations, it may increase low-density lipoprotein in type IV hyperlipoproteinemia. A 5-year placebo-controlled study showed that this product can reduce the occurrence of severe coronary heart disease sudden death and myocardial infarction. Long-term administration of 10 times the human dose to rats increased the incidence of liver malignancies and benign testicular tumors.

Chemical name: 2,2-dimethyl-5-(2,5-dimethylphenyloxy)-pentanoic acid Molecular weight: C15H22O3

The content of this product is white powder.

Used for hyperlipidemia; suitable for patients with severe type IV or V hyperlipoproteinemia, high risk of coronary heart disease and those who have not responded to diet control, weight loss and other treatments; also suitable for patients with type IIb hyperlipoproteinemia, high risk of coronary heart disease and those who have not responded to diet control, weight loss and other blood lipid regulating drugs; in view of the potential carcinogenicity of this product to humans, its use should be strictly limited to the specified indications, and the drug should be discontinued promptly if the therapeutic effect is not obvious.

Usual oral dose for adults: 0.3-0.6 g (1-2 tablets) at a time, twice a day, 30 minutes before breakfast and dinner.

1. The most common adverse reactions are gastrointestinal discomfort, such as indigestion, anorexia, nausea, vomiting, fullness, stomach discomfort, etc. Other less common adverse reactions include headache, dizziness, fatigue, rash, itching, impotence, etc. 2. Occasionally there is cholelithiasis or myositis (myalgia, fatigue). This product is a derivative of clofibric acid, which may cause myositis, myopathy and rhabdomyolysis syndrome, leading to increased blood creatine phosphokinase. Rhabdomyolysis occurs, mainly manifested by myalgia combined with increased blood creatine phosphokinase, myoglobinuria, and may lead to renal failure, but it is rare. In patients with nephrotic syndrome and other renal damage that lead to decreased blood albumin or patients with hyperthyroidism, the risk of myopathy increases. 3. Occasionally there are liver function tests (blood aminotransferase, lactate dehydrogenase, bilirubin,

1. Patients who are allergic to gemfibrozil are contraindicated. 2. Patients with gallbladder disease or cholelithiasis are contraindicated because this product may aggravate the symptoms of gallbladder disease. Patients with liver dysfunction or primary biliary cirrhosis are contraindicated because this product may promote increased cholesterol excretion and increase the already high cholesterol level. 3. Patients with severe renal insufficiency are contraindicated because taking this product may cause rhabdomyolysis and severe hyperkalemia in patients with renal insufficiency. Patients with serum protein decrease caused by nephrotic syndrome are contraindicated because they have an increased risk of myopathy.

Precautions for children: There is insufficient research on the use of this product in children, so the pros and cons must be weighed when using it. Precautions for pregnancy and lactation: High doses of this product can cause fetal death in animals, but no human studies have been reported. It is unknown whether this product enters breast milk, so pregnant and lactating women should not take this product. Precautions for the elderly: If the elderly have poor renal function, the dosage of this product should be appropriately reduced.

1. This product can significantly enhance the effect of oral anticoagulants. When used with them, you should pay attention to reducing the dose of oral anticoagulants and monitor the prothrombin time frequently to adjust the dose of anticoagulants. Its mechanism of action is still uncertain. It may be because this product can replace warfarin and other drugs from their protein binding sites, thereby enhancing their effects. 2. When this product is used in combination with other drugs with high protein binding rates, it can also replace them from the protein binding sites, leading to enhanced effects, such as tolbutamide and other sulfonylurea hypoglycemic drugs, phenytoin, furosemide, etc. If the above drugs are taken during lipid-lowering treatment, the doses of hypoglycemic drugs and other drugs should be adjusted. 3. The combined use of clofibric acid derivatives and HMG-CoA reductase inhibitors, such as lovastatin, to treat hyperlipidemia will increase the occurrence of severe muscle toxicity of both.

Sealed in a cool, dry place.

36 months